Drugs that contain Sapropterin Dihydrochloride
1. Drug name - KUVAN
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8067416 | BIOMARIN PHARM | Methods and compositions for the treatment of metabolic disorders |
Nov, 2024
(2 years from now) | |
| US9433624 | BIOMARIN PHARM | Methods and compositions for the treatment of metabolic disorders |
Nov, 2024
(2 years from now) | |
| US7612073 | BIOMARIN PHARM | Methods of administering tetrahydrobiopterin, associated compositions, and methods of measuring |
Nov, 2024
(2 years from now) | |
| US7727987 | BIOMARIN PHARM | Crystalline forms of (6R)-L-erythro-tetrahydrobiopterin dihydrochloride |
Nov, 2024
(2 years from now) | |
| US8318745 | BIOMARIN PHARM | Crystalline forms of (6R)-L-erythro-tetrahydrobiopterin dihydrochloride |
Nov, 2024
(2 years from now) | |
| US7566714 | BIOMARIN PHARM | Methods and compositions for the treatment of metabolic disorders |
Nov, 2024
(2 years from now) | |
| USRE43797 | BIOMARIN PHARM | Methods of administering tetrahydrobiopterin |
Nov, 2024
(2 years from now) | |
|
USRE43797
(Pediatric) | BIOMARIN PHARM | Methods of administering tetrahydrobiopterin |
May, 2025
(2 years from now) | |
|
US7612073
(Pediatric) | BIOMARIN PHARM | Methods of administering tetrahydrobiopterin, associated compositions, and methods of measuring |
May, 2025
(2 years from now) | |
|
US8067416
(Pediatric) | BIOMARIN PHARM | Methods and compositions for the treatment of metabolic disorders |
May, 2025
(2 years from now) | |
|
US7566714
(Pediatric) | BIOMARIN PHARM | Methods and compositions for the treatment of metabolic disorders |
May, 2025
(2 years from now) | |
|
US7727987
(Pediatric) | BIOMARIN PHARM | Crystalline forms of (6R)-L-erythro-tetrahydrobiopterin dihydrochloride |
May, 2025
(2 years from now) | |
|
US8318745
(Pediatric) | BIOMARIN PHARM | Crystalline forms of (6R)-L-erythro-tetrahydrobiopterin dihydrochloride |
May, 2025
(2 years from now) | |
| US8003126 | BIOMARIN PHARM | Stable tablet formulation |
Nov, 2025
(3 years from now) | |
| US7566462 | BIOMARIN PHARM | Stable tablet formulation |
Nov, 2025
(3 years from now) | |
|
US7566462
(Pediatric) | BIOMARIN PHARM | Stable tablet formulation |
May, 2026
(3 years from now) | |
|
US8003126
(Pediatric) | BIOMARIN PHARM | Stable tablet formulation |
May, 2026
(3 years from now) | |
| US9216178 | BIOMARIN PHARM | Dry blend formulation of tetrahydrobiopterin |
Nov, 2032
(10 years from now) | |
Treatment: Method of use for reducing blood phenylalanine levels in a human suffering from hyperphenylalaninemia; To reduce blood phenylalanine levels in patients with hyperphenylalaninemia due to tetra hydrobiopterin responsive phenylketonuria. kuvan should be taken orally with food to increase absorption; For reducing blood phenylalanine levels in a human suffering from hyperphenylalaninemia; To reduce blood phenylalanine (phe) levels in patients with hyperphenylalaninemia (hpa)
Dosage: TABLET;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| 100MG | TABLET;ORAL | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.